Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis
Mon, 06/01/2026 – 13:19
Read more about Scemblix® continued to show superior efficacy and favorable safet…
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis
Mon, 06/01/2026 – 07:19
Read more about Novartis data at EULAR 2026 demonstrates momentum for broad immunology po…
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis
Mon, 06/01/2026 – 07:19
Read more about Novartis data at EULAR 2026 demonstrates momentum for broad immunology po…
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
arcticnovartis
Mon, 06/01/2026 – 07:19
Read more about Novartis data at EULAR 2026 demonstrates momentum for broad immunology po…
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
arcticnovartis
Sun, 05/31/2026 – 07:19
Read more about Pluvicto™ demonstrated consistent efficacy across key patient subgroups …
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis
Tue, 05/26/2026 – 07:19
Read more about New Novartis data at ERA 2026 advance scientific understanding of kidney disea…
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
arcticnovartis
Tue, 05/26/2026 – 07:19
Read more about New Novartis data at ERA 2026 advance scientific understanding of kidney disea…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
arcticnovartis
Thu, 05/21/2026 – 07:19
Read more about Novartis advances RLT innovation and reinforces leader…
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
arcticnovartis
Sun, 05/17/2026 – 21:34
Read more about New PSMAddition data show 58% lower risk of PSA progression with Pluv…
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
arcticnovartis
Thu, 05/07/2026 – 15:02
Read more about Novartis breaks ground on Denton, Texas radioligand therapy site; const…
